Shares of ResMed Inc. RMD rallied 1.61% to $237.13 Thursday, on what proved to be an all-around poor trading session for the ...

The stock's rise snapped a four-day losing streak.

Analyst Lyanne Harrison of Bank of America Securities reiterated a Buy rating on Resmed (RMD – Research Report), retaining the price target of ...

Ritholtz Wealth Management lessened its holdings in shares of ResMed Inc. (NYSE:RMD – Free Report) by 79.7% in the fourth ...

Aaron Wealth Advisors LLC lifted its holdings in shares of ResMed Inc. (NYSE:RMD – Free Report) by 25.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional ...

The investing pros at Firetrail forecast another strong year for ResMed shares in 2025. The post ResMed shares are up 42% in ...

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

Investing.com -- Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure ...

For investors, reporting season can bring good news, but also unwanted surprises. Here are five ASX shares our writers have ...